Therapeutics News and Research

RSS

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

18 Aug 2010

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

18 Aug 2010

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and MonoSol Rx, the leader in developing and manufacturing pharmaceutical films based on its proprietary PharmFilm drug delivery technology, today announced the filing of a provisional US patent application for "Nanoparticle Film Delivery Systems." The applications submitted to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.

18 Aug 2010

AMT's MAA for LPLD gene therapy product Glybera on schedule

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.

18 Aug 2010

Researchers discover sugars that fight body's natural defenses, vaccines

A special set of sugars found on some disease-causing pathogens helps those pathogens fight the body's natural defenses as well as vaccines, say two Iowa State University researchers.This discovery may be a first step in understanding a disease family that includes tuberculosis for which there are currently no good vaccines or cures.Nicola Pohl, professor of chemistry, and Christine Petersen, assistant professor of veterinary pathology, discovered that a natural coating of sugar interacts with the body's defense cells to dampen its own immune response.

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

TRI awarded RSC contract to support domestic, international clinical research programs

Technical Resources International, Inc. is pleased to announce that TRI has been awarded the Regulatory Support Center contract by the U.S. National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health, Department of Health and Human Services.

17 Aug 2010

PRA International to host audio conference on CV drug development strategy

PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

17 Aug 2010

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

A protein associated with cancer progression when abundant inside of tumors also unexpectedly regulates the creation of new blood vessels that feed the tumor outside, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the August edition of Cancer Cell.

17 Aug 2010

MMV joins Pool for Open Innovation against neglected tropical diseases

The Medicines for Malaria Venture (MMV) today became the first product development partnership (PDP) to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases. MMV joins GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in contributing to the Pool, which is administered by BIO Ventures for Global Health (BVGH).

17 Aug 2010

Pernix Therapeutics reports decrease in net sales for 2010 second quarter

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced results for the quarter and six months ended June 30, 2010.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Weikang Bio-Technology second-quarter revenue decreases 20.5% to $10.5 million

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced its fiscal 2010 second quarter results for period ended June 30, 2010.

16 Aug 2010

NeoStem second-quarter revenues increase 26% to $19.4 million

NeoStem, Inc. an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units, U.S. adult stem cells, China adult stem cells, and China pharmaceuticals is today providing results of its second quarter 2010.

16 Aug 2010

PLC Systems second-quarter total revenues decrease to $1,019,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and six month periods ended June 30, 2010.

16 Aug 2010

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.

16 Aug 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

EntreMed, Inc.,a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.

16 Aug 2010

Nile Therapeutics second quarter 2010 net loss decreases to $1.5 million

Nile Therapeutics, Inc.,a company focused on the development of novel therapeutics for heart failure patients, today announced its second quarter financial results for 2010.

16 Aug 2010

Therapeutics News and Research

Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Midatech Group, MonoSol Rx file patent to enable commercialization of drug delivery technology

AMT's MAA for LPLD gene therapy product Glybera on schedule

Researchers discover sugars that fight body's natural defenses, vaccines

NCI grants SBIR award to MabVax Therapeutics

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

TRI awarded RSC contract to support domestic, international clinical research programs

PRA International to host audio conference on CV drug development strategy

Nanoparticle-based gene silencing system inhibits angiogenesis process in tumor growth

MMV joins Pool for Open Innovation against neglected tropical diseases

Pernix Therapeutics reports decrease in net sales for 2010 second quarter

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Weikang Bio-Technology second-quarter revenue decreases 20.5% to $10.5 million

NeoStem second-quarter revenues increase 26% to $19.4 million

PLC Systems second-quarter total revenues decrease to $1,019,000

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

EntreMed second quarter 2010 net loss increases to $0.62 per share

Nile Therapeutics second quarter 2010 net loss decreases to $1.5 million

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News